Amylyx Pharmaceuticals (AMLX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Amylyx Pharmaceuticals (AMLX) is Neutral.

The composite score behind that read is -0.18, weighing +0.26 of bullish evidence against -0.29 bearish.

Amylyx Pharmaceuticals last closed at $27.78, -0.04% on the session.

Against the IVW growth benchmark the position is -0.96% over the forecast window.

The read is built from 13 underlying insights — 3 bullish and 10 bearish.

Agreement across those insights is 77%.

Amylyx Pharmaceuticals has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Amylyx Pharmaceuticals in the 17th percentile on return on equity, where 100 is best.

Amylyx Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $3.49B.

StockMap tracks Amylyx Pharmaceuticals as the 28th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Amylyx Pharmaceuticals ranks 54th of 128 in the group, against a group median of -0.24.